TGN1412 CASE STUDY
Retrieved 4 June Monoclonal antibodies for the immune system. Retrieved from ” https: Additional concern with the administration of a novel biological agent is the dosing interval between subjects. Preclinical studies in these drugs concluded that non-human primates appear not to predict cytokine release in humans. These studies revealed a consistent tissue staining in lymphoid tissue as expected demonstrating target-tissue specificity of CD28 superagonist.
N Engl J Med. To function as an agonist, it has been suggested that TGN needs to be a whole antibody , including the constant Fc region. Preparing for first-in-man studies: At this point, trial was stopped for all other patients. Tentative opinions from an as-yet uncompleted inquiry suggest that the problems resulted from “unforeseen biological action in humans”, rather than breach of trial protocols, and the case therefore has had important ramifications for future trials of potentially powerful clinical agents. The more active of the two, TGN originally called 5.
This unprecedented outcome of the TGN trial, raised many questions regarding safety processes implemented during clinical trials.
TGN From Discovery to Disaster
Scrutinizing preclinical trials of antibody-based medicines. Archived from the original on 5 December As of Marchthere appear to have been two issues. Journal of Allergy and Clinical Immunology. The more active of the two, 5. All six of the trial subjects who received the drug were male, aged 19 to 34 median An investigation by the UK drug regulator reported that the reaction was not due to contamination of the dose, or an incorrect dose being administered, but suggested that the problem was due to “on target” effects of the drug.
Retrieved 17 March Retrieved 14 August The US patent application states “it could be shown in a pilot study that an in vitro administration of anti-human CDSuperMAB induces in a rhesus monkey in vivo a profound activation of T cells, without clinically visible side effects” and goes on to say “This antibody—in spite of its strong T cell-stimulatory properties—is very well tolerated in vivo, in contrast to all other known T cell activating substances.
Fourth Estate,pp. Even a pilot study on 43 patients treated for 2 and 4 weeks duration with Fialuridine did not reveal any signs of hepatic toxicity on initial examination. In addition, most of the adverse events associated with cytokine release such as headache, nausea and myalgia are subjective.
A phase-1, single-centre, double-blind, randomised, placebo-controlled, single escalating dose study, to assess the safety, pharmacokinetics, pharmacodynamics and immunogenicity of TGN administered intravenously to healthy volunteers. Journal of the Royal Statistical Society. Shamoo A, Woeckner E.
Adapted from Dayan and Wraith[ 8 ]. Inthe failure to predict a severe cytokine release syndrome in humans was explained.
TGN1412: From Discovery to Disaster
One of the placebo-receiving participants has explained the doses were given with 2-minute intervals. Manipulation of regulatory T-cell number and function with CDspecific monoclonal antibodies.
N Engl J Med. However, TGN is a genetically engineered humanised form of the anti-CD28 antibody from the investigational mouse. The first patient sstudy transferred to the Northwick Park hospital’s intensive care unit 12 hours after infusion, with the others following within the next 4 hours.
Since activation of regulatory T cells can be useful for the treatment of a variety of autoimmune diseases and cancer, they were investigated for their therapeutic potential in different animal models for their superagonist activity. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
A first-in-human trial, which had successful preclinical testing, obtained regulatory approval ended abruptly after the first dose. For this purpose, it was decided to conduct the trials on healthy human volunteers because disease free subjects have comparable CD28 receptors as in case of rhematioid arthritis or B-cell lymphoma.
The comments on the company webpage and in the patent application indicated that the company knew that this type of drug could cause a severe cytokine release syndrome. Edmond, OK Mailing address Email: Preclinical studies in these drugs concluded that non-human primates appear not to predict cytokine release in humans.
Moreover, when the last volunteer was to be infused, the first volunteer had already started showing adverse effects.